HTDS finalizes contract details with Indian pharmaceutical company

Dec 1 2009NewsGuard 100/100 Score

Hard to Treat Diseases' (HTDS; http://www.htdsmedical.com/) operating subsidiary Mellow Hope finalized contract details with one of the largest manufacturer of intravenous medication in India. This contract promises additional increase in revenues for Hard to Treat Diseases in the following quarters.

The contract between HTDS and the Indian company secures the supply of raw pharmaceutical material to the Indian pharmaceutical company in the range of about 1 million USD. Mellow Hope will be ready to release the shipments shortly. This contract is bound to strengthen Mellow Hope's sales and further increase the value of HTDS.

HTDS' CEO Terry Yuan said, "With our earlier, 4 million USD deal with Indian Hetero Ltd. and our H1N1 vaccine deal with Chile, this is another great news for HTDS. Our business has truly grown in past few months and the investors must appreciate our achievements. With the world growing smaller and smaller, the vaccination market and industry are bound to grow bigger. That's the global trend, and HTDS is definitely a part of it."

Source:

Hard to Treat Diseases

Posted in: Pharmaceutical News

Tags: , , ,

Comments (0)

Suggested Reading

Obesity crisis in the U.S. expected to worsen by 2050
Combination therapy shows promising results in treating stage 3 melanoma
Obesity medication liraglutide is safe and effective in children aged 6 to <12 years
Study shows how a single defective BRCA1 gene accelerates cancer development
Early RSV vaccination in pregnancy provides best protection for newborns
GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes
Study focuses on COPD progression in younger populations
New target identified for potential ALS therapy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Antibiotic resistance threatens millions of lives worldwide